Johnson & Johnson Faces Canada-Wide Talc Lawsuit After Court Certification

TORONTO, ON – March 06, 2026 – A landmark decision by the Ontario Superior Court of Justice has certified a Canada-wide class action lawsuit against Johnson & Johnson, allowing a case alleging the company’s iconic Baby Powder caused ovarian cancer to proceed on behalf of thousands of Canadians.

The certification, granted by Justice Leiper on March 4, 2026, marks a significant procedural victory for plaintiffs who claim the multinational giant failed to adequately warn them of the potential cancer risks associated with the perineal use of its talc-based products. The lawsuit seeks damages for what the plaintiffs' claim is decades of misconduct and misleading marketing regarding the product's safety.

A Crucial Step Forward for Canadian Plaintiffs

The court's decision is not a ruling on the merits of the case but a critical gateway, confirming that the lawsuit meets the necessary criteria to proceed as a class action. This allows countless individuals with similar claims to pursue justice collectively, a path that would be financially and logistically impossible for most to walk alone.

This week's ruling finalizes a two-step process. In a decision on June 25, 2025, Justice Leiper had already found that the plaintiffs met four of the five necessary criteria for certification. The final criterion was put on hold pending developments in a similar case in British Columbia. Following those developments in late 2025, the parties returned to the Ontario court, where Justice Leiper has now affirmed that all requirements have been met.

The lawsuit’s claims are not limited to personal injury. It also includes allegations under Canada’s Competition Act and provincial consumer protection laws, arguing that Johnson & Johnson engaged in false and misleading representations about the safety of its Baby Powder.

The law firms representing the plaintiffs, Rochon Genova and Howie, Sacks & Henry LLP, issued a statement welcoming the development as a move that "advances the rights of vulnerable people across Canada." While Johnson & Johnson continues to deny the allegations, the certification opens a new and significant legal front for the company north of the border.

Echoes of a Larger Legal Battle in the U.S.

The Canadian case is unfolding in the shadow of massive and long-running litigation in the United States, where Johnson & Johnson faces tens of thousands of similar lawsuits. As of early March 2026, the U.S. multidistrict litigation (MDL) comprised over 67,000 plaintiffs alleging links between the company's talc products and cancers, including ovarian cancer and mesothelioma.

American juries have delivered a series of staggering verdicts against the company in recent years. In December 2025, a Baltimore jury awarded over $1.5 billion to a single plaintiff. This followed numerous other multi-million dollar verdicts, including a $110 million award in 2017 and a $72 million award in 2016. While many of these are subject to appeals, they signal a growing legal consensus holding the company accountable for its marketing and product safety warnings.

In response to its mounting legal troubles, Johnson & Johnson has repeatedly attempted to use the U.S. bankruptcy system to manage its talc-related liabilities. The company created a subsidiary, LTL Management, to absorb the lawsuits before declaring bankruptcy. However, federal appeals courts have consistently rejected this strategy, with a third bankruptcy attempt dismissed as recently as March 2025. These failed maneuvers have left the company to face the litigation head-on in court.

While the U.S. verdicts have no direct binding authority in Canada, they establish a powerful precedent and provide a potential roadmap for the Canadian plaintiffs regarding legal strategy and potential damages.

The Science Under Scrutiny

At the heart of this global legal firestorm is a decades-long scientific debate over the safety of talc, a naturally occurring mineral. The lawsuits allege that talc particles, when used for perineal hygiene, can travel into the reproductive system and cause inflammation, leading to the development of epithelial ovarian cancer.

Research suggesting a potential link dates back to the 1970s, with some subsequent studies indicating that long-term perineal talc use could increase a woman's risk of ovarian cancer by as much as 30 to 40 percent. Johnson & Johnson has consistently and vigorously disputed these claims, maintaining that decades of scientific studies by medical experts worldwide support the safety of its cosmetic talc.

However, the legal tide appears to be turning in favor of the plaintiffs' scientific arguments. In a pivotal ruling in January 2026 within the U.S. litigation, a court-appointed special master concluded that juries should be permitted to hear expert testimony linking talc use to ovarian cancer. The master found that the plaintiffs' experts used reliable and mainstream scientific methods to reach their conclusions, reinforcing a similar ruling from 2020. This legal validation of the plaintiffs' core scientific evidence could prove influential as the Canadian case proceeds.

Broader Implications for Corporate Accountability

The certification of this Canada-wide class action represents more than just a legal challenge to a single product. It raises fundamental questions about corporate responsibility, transparency in marketing, and the effectiveness of Canada's consumer protection regulations.

The case will scrutinize the extent of a corporation's duty to warn consumers about potential risks, even when a complete scientific consensus is debated. The allegations of "false and misleading representations" under the Competition Act put the company's marketing history directly in the legal crosshairs. A victory for the plaintiffs could set a powerful precedent, compelling companies across all industries to be more forthcoming about potential product risks and less reliant on portraying a flawless safety record.

Furthermore, the outcome could have a ripple effect on regulatory bodies like Health Canada, which oversees the safety of cosmetic products. The high-profile nature of the litigation may prompt a re-evaluation of the standards and labeling requirements for products containing talc and other common ingredients. For now, thousands of Canadian women and their families have been granted the right to have their claims heard collectively, marking the beginning of what is sure to be a long and closely watched legal battle for corporate accountability on Canadian soil.